Driving Innovation and Extending Its Global Reach
Rentschler Biopharma Expands Its International Activities
Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025." As an important part of this strategy, the company plans to offer new services and business models along the value chain in the coming years and secure its technological leadership through a variety of innovations. This year, Rentschler Biopharma has taken important steps towards realizing its vision.
In early 2019, the company acquired a manufacturing facility from an affiliate of Shire in response to requests from North American clients to bring its expertise and full-service CDMO offerings closer to them. The site with roughly 80 employees near Boston in Milford, MA, USA is Rentschler Biopharma’s first facility outside of Europe.The acquired facility, located in an important biotechnology hub, increases Rentschler Biopharma’s flexibility and manufacturing capacity. The site is being qualified as a multi-product manufacturing facility, enabling the company to diversify and to address client requirements. The expansion of capacity and capabilities in Milford has already started.
With access to development and manufacturing facilities in both Europe and the United States, the company will be able to effectively leverage its expertise in advanced technologies that facilitate the robust, scalable production of complex biomolecules.
Driving Innovation through Strategic Alliances
North America is not the only region where Rentschler Biopharma is stepping up its international activities. At the beginning of October, the company announced that it is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
Through its highly productive and fruitful collaboration with SPI, the Laupheim-based CDMO said it has secured new contracts with Japanese pharmaceutical companies. Going forward, the two partners will work together with clients to outline projects from early clinical stage up to commercial launch, thereby ensuring optimal service.
As one of the world’s largest biopharmaceutical markets, Japan is an important area of growth for Rentschler Biopharma, says CEO Frank Mathias, adding that management has been impressed by its Japanese partner’s strong network and extensive experience in contract manufacturing and supply.
Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support.
The company serves as a solution partner for its clients and continuously works to improve its processes and implement new technologies with the goal of enabling better, faster, more cost effective development and production.